Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab vs investigator's choice in recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck
2013-003622-86Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in head and neck squamous cell carcinoma (HNSCC) and Pharyngeal squamous cell carcinoma (PSCC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Progression-Free Survival and Overall Survival. Started Apr 2014; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Pharyngeal squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on 2013-003622-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003622-86.